A considerable body of preclinical evidence supports TAAR1 as a promising target for the treatment of metabolic syndrome and obesity, substance abuse, sleep disorders characterized by changes in REM sleep, and potentially mood and anxiety disorders. The gene discussed is TAAR1; the disease is sleep disorder.